

# Neuroendocrine Carcinoma: Epidemiology Forecasting Intelligence

<https://marketpublishers.com/r/N2B7630C099EN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,500.00 (Single User License)

ID: N2B7630C099EN

## Abstracts

CmaxInsight's "Neuroendocrine Carcinoma-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Neuroendocrine Carcinoma epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:

Incidence and prevalence

Diagnosis rate, treatment rate and mortality patterns

Epidemiology-based forecasting and disease trends

Size of different patient segments in a disease area

Population based: disease occurrence, co-morbidities and treatment patterns

Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:

Disease overview, causes, symptoms, classification, risk factor,  
pathophysiology, diagnosis and treatment

## Patient treatment journey

Treatment algorithm and guidelines

Assesses the disease risk and burden

Highlights the unmet needs

Market driver and barrier

Growth opportunities and market trend analysis

## Methodology

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.

To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.

All of the sources used to generate the data and analysis have been identified in the report.

**Note:** Systematic review of the epidemiological literature is also provided for full transparency into research and methods. This report can be delivered to the clients within 4-5 business days.

## Contents

### **1. REPORT INTRODUCTION**

### **2. NEUROENDOCRINE CARCINOMA EPIDEMIOLOGY OVERVIEW AT A GLANCE**

### **3. MARKET SHARE DISTRIBUTION OF NEUROENDOCRINE CARCINOMA**

### **4. DISEASE BACKGROUND AND OVERVIEW: NEUROENDOCRINE CARCINOMA**

#### 4.1. Introduction

#### 4.2. Signs and Symptoms

#### 4.3. Etiology

#### 4.4. Risk Factors

#### 4.5. Pathophysiology

#### 4.6. Diagnostic Landscape

##### 4.6.1. Diagnostic Practices

##### 4.6.2. Diagnostic Criteria

##### 4.6.3. Diagnostic Recommendations

#### 4.7. Treatment Landscape

##### 4.7.1. Current Treatment Practices

##### 4.7.2. Treatment Algorithm

##### 4.7.3. Treatment Recommendations

### **5. NEUROENDOCRINE CARCINOMA EPIDEMIOLOGY**

#### 5.1. Key Findings

#### 5.2. Assumptions & Rationale

#### 5.3. 7MM Epidemiology

### **6. EPIDEMIOLOGY OF NEUROENDOCRINE CARCINOMA BY COUNTRIES**

### **7. UNITED STATES**

#### 7.1. Assumptions and Rationale

#### 7.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma

#### 7.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*

#### 7.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*

#### 7.5. Diagnosed Cases of Neuroendocrine Carcinoma

## 7.6. Treated Cases of Neuroendocrine Carcinoma

### 8. EU5

#### 8.1. Germany

- 8.1.1. Assumptions and Rationale
- 8.1.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma
- 8.1.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*
- 8.1.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*
- 8.1.5. Diagnosed Cases of Neuroendocrine Carcinoma
- 8.1.6. Treated Cases of Neuroendocrine Carcinoma

#### 8.2. France

- 8.2.1. Assumptions and Rationale
- 8.2.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma
- 8.2.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*
- 8.2.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*
- 8.2.5. Diagnosed Cases of Neuroendocrine Carcinoma
- 8.2.6. Treated Cases of Neuroendocrine Carcinoma

#### 8.3. United Kingdom

- 8.3.1. Assumptions and Rationale
- 8.3.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma
- 8.3.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*
- 8.3.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*
- 8.3.5. Diagnosed Cases of Neuroendocrine Carcinoma
- 8.3.6. Treated Cases of Neuroendocrine Carcinoma

#### 8.4. Spain

- 8.4.1. Assumptions and Rationale
- 8.4.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma
- 8.4.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*
- 8.4.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*
- 8.4.5. Diagnosed Cases of Neuroendocrine Carcinoma
- 8.4.6. Treated Cases of Neuroendocrine Carcinoma

#### 8.5. Italy

- 8.5.1. Assumptions and Rationale
- 8.5.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma
- 8.5.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*
- 8.5.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*
- 8.5.5. Diagnosed Cases of Neuroendocrine Carcinoma
- 8.5.6. Treated Cases of Neuroendocrine Carcinoma

## **9. JAPAN**

- 9.1. Assumptions and Rationale
- 9.2. Prevalent/Incident Cases of Neuroendocrine Carcinoma
- 9.3. Sub-Type Specific cases of Neuroendocrine Carcinoma\*
- 9.4. Sex- Specific Cases of Neuroendocrine Carcinoma\*
- 9.5. Diagnosed Cases of Neuroendocrine Carcinoma
- 9.6. Treated Cases of Neuroendocrine Carcinoma

## **10. UNMET NEEDS**

Appendix

Report Methodology

Sources Used

Disclaimer

About CmaxInsight

\*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.

## List Of Tables

### LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM

Table 2: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in United States

Table 4: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in United States\*

Table 5: Sex- Specific Cases of the Neuroendocrine Carcinoma in United States\*

Table 6: Diagnosed Cases of the Neuroendocrine Carcinoma in United States

Table 7: Treated Cases of the Neuroendocrine Carcinoma in United States

Table 8: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Germany

Table 9: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Germany\*

Table 10: Sex- Specific Cases of the Neuroendocrine Carcinoma in Germany\*

Table 11: Diagnosed Cases of the Neuroendocrine Carcinoma in Germany

Table 12: Treated Cases of the Neuroendocrine Carcinoma in Germany

Table 13: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in France

Table 14: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in France\*

Table 15: Sex- Specific Cases of the Neuroendocrine Carcinoma in France\*

Table 16: Diagnosed Cases of the Neuroendocrine Carcinoma in France

Table 17: Treated Cases of the Neuroendocrine Carcinoma in France

Table 18: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Italy

Table 19: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Italy\*

Table 20: Sex- Specific Cases of the Neuroendocrine Carcinoma in Italy\*

Table 21: Diagnosed Cases of the Neuroendocrine Carcinoma in Italy

Table 22: Treated Cases of the Neuroendocrine Carcinoma in Italy

Table 23: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Spain

Table 24: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Spain\*

Table 25: Sex- Specific Cases of the Neuroendocrine Carcinoma in Spain\*

Table 26: Diagnosed Cases of the Neuroendocrine Carcinoma in Spain

Table 27: Treated Cases of the Neuroendocrine Carcinoma in Spain

Table 28: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in UK

Table 29: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in UK\*

Table 30: Sex- Specific Cases of the Neuroendocrine Carcinoma in UK\*

Table 31: Diagnosed Cases of the Neuroendocrine Carcinoma in UK

Table 32: Treated Cases of the Neuroendocrine Carcinoma in UK

Table 33: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Japan

Table 34: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Japan\*

Table 35: Sex- Specific Cases of the Neuroendocrine Carcinoma in Japan\*

Table 36: Diagnosed Cases of the Neuroendocrine Carcinoma in Japan

Table 37: Treated Cases of the Neuroendocrine Carcinoma in Japan

\*Indication Specific

## List Of Figures

### LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM

Figure 2: Total Prevalent/Incident Cases of the Neuroendocrine Carcinoma in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in United States

Figure 4: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in United States\*

Figure 5: Sex- Specific Cases of the Neuroendocrine Carcinoma in United States\*

Figure 6: Diagnosed Cases of the Neuroendocrine Carcinoma in United States

Figure 7: Treated Cases of the Neuroendocrine Carcinoma in United States

Figure 8: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Germany

Figure 9: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Germany\*

Figure 10: Sex- Specific Cases of the Neuroendocrine Carcinoma in Germany\*

Figure 11: Diagnosed Cases of the Neuroendocrine Carcinoma in Germany

Figure 12: Treated Cases of the Neuroendocrine Carcinoma in Germany

Figure 13: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in France

Figure 14: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in France\*

Figure 15: Sex- Specific Cases of the Neuroendocrine Carcinoma in France\*

Figure 16: Diagnosed Cases of the Neuroendocrine Carcinoma in France

Figure 17: Treated Cases of the Neuroendocrine Carcinoma in United France

Figure 18: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Italy

Figure 19: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Italy\*

Figure 20: Sex- Specific Cases of the Neuroendocrine Carcinoma in Italy\*

Figure 21: Diagnosed Cases of the Neuroendocrine Carcinoma in Italy

Figure 22: Treated Cases of the Neuroendocrine Carcinoma in Italy

Figure 23: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Spain

Figure 24: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Spain\*

Figure 25: Sex- Specific Cases of the Neuroendocrine Carcinoma in Spain\*

Figure 26: Diagnosed Cases of the Neuroendocrine Carcinoma in Spain

Figure 27: Treated Cases of the Neuroendocrine Carcinoma in Spain

Figure 28: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in UK

Figure 29: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in UK\*

Figure 30: Sex- Specific Cases of the Neuroendocrine Carcinoma in UK\*

Figure 31: Diagnosed Cases of the Neuroendocrine Carcinoma in UK

Figure 32: Treated Cases of the Neuroendocrine Carcinoma in UK

Figure 33: Prevalent/Incident Cases of the Neuroendocrine Carcinoma in Japan

Figure 34: Sub-Type Specific Cases of the Neuroendocrine Carcinoma in Japan\*



Figure 35: Sex- Specific Cases of the Neuroendocrine Carcinoma in Japan\*

Figure 36: Diagnosed Cases of the Neuroendocrine Carcinoma in Japan

Figure 37: Treated Cases of the Neuroendocrine Carcinoma in Japan

\*Indication Specific

## I would like to order

Product name: Neuroendocrine Carcinoma: Epidemiology Forecasting Intelligence

Product link: <https://marketpublishers.com/r/N2B7630C099EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N2B7630C099EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970